drugset / Trial / NCT04218513

Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection

NCT04218513

Phase 1 Completed 24 enrolled Nanjing Yoko Biomedical Co., Ltd.
RandomizedCrossoverOpen-labelBasic science

Summary

An experiment to evaluate the drug-drug interaction of formula edaravone and formula 2-aminoethanesulfonic acid in compound edaravone injection.

Timeline

Start
2019-05-10
Primary completion
2019-05-31
Completion
2019-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-Aminoethanesulfonic Acid Unknown 600 mg Intravenous
Subject Edaravone Unknown 30 mg Intravenous

Indications

No indication recorded.